AP NEWS

Opioid-Induced Constipation - Pipeline Insight, 2019 - ResearchAndMarkets.com

January 22, 2019

DUBLIN--(BUSINESS WIRE)--Jan 22, 2019--The “Opioid-Induced Constipation - Pipeline Insight, 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Opioid-Induced Constipation development.

The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Opioid-Induced Constipation

Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Pipeline Therapeutics assessment of products for Opioid-Induced Constipation

The report assesses the active Opioid-Induced Constipation pipeline products by developmental stage, product type, molecule type, and administration route.

Companies Featured

Develco Pharma Schweiz AG Ironwood Pharmaceuticals Inc. Shionogi & Co. Ltd. Sucampo Pharmaceuticals Inc. Synergy Pharmaceuticals Inc.

Topics Covered

1. Report Introduction

2. Opioid-Induced Constipation Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Products in Clinical Stage

6. Products in Pre-Clinical & Discovery Stage

7. Therapeutic Assessment

8. Inactive Products

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/5hdmk4/opioidinduced?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190122005475/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Gastrointestinal Drugs ,Addiction Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/22/2019 06:52 AM/DISC: 01/22/2019 06:52 AM

http://www.businesswire.com/news/home/20190122005475/en

AP RADIO
Update hourly